Atle Fund Management AB Invests $4.26 Million in Abivax SA Sponsored ADR $ABVX

Atle Fund Management AB bought a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 31,590 shares of the company’s stock, valued at approximately $4,260,000. Abivax comprises about 1.4% of Atle Fund Management AB’s investment portfolio, making the stock its 28th largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in ABVX. EverSource Wealth Advisors LLC raised its position in shares of Abivax by 4,612.5% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares during the period. WPG Advisers LLC boosted its stake in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after acquiring an additional 253 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in shares of Abivax in the fourth quarter valued at about $67,000. Hantz Financial Services Inc. purchased a new stake in shares of Abivax in the third quarter valued at about $52,000. Finally, Assetmark Inc. purchased a new stake in shares of Abivax in the fourth quarter valued at about $84,000. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Abivax Stock Performance

Shares of NASDAQ ABVX opened at $113.73 on Wednesday. Abivax SA Sponsored ADR has a 1 year low of $5.59 and a 1 year high of $148.83. The firm’s 50 day moving average price is $117.17 and its 200 day moving average price is $118.70. The firm has a market cap of $9.06 billion, a P/E ratio of -21.18 and a beta of 0.84.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The business had revenue of $0.52 million for the quarter. As a group, equities analysts predict that Abivax SA Sponsored ADR will post -3.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. BTIG Research reaffirmed a “buy” rating and issued a $150.00 target price on shares of Abivax in a report on Wednesday, February 25th. Barclays raised their price objective on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Wedbush began coverage on shares of Abivax in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price objective for the company. Oddo Bhf restated an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.15.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.